Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• Sánchez-MuñozAPérez-RuizEJiménezBTargeted therapy of metastatic breast cancerClin Transl Oncol2009111064365019828406
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• MilesDWChanADirixLYPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol201028203239324720498403
   PubMed Web of Science ®Google Scholar
• RobertNJDiérasVGlaspyJRIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancerJ Clin Oncol201129101252126021383283
   PubMed Web of Science ®Google Scholar
• CaiJMaHHuangFCorrelation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysisWorld J Surg Oncol20131130624283603
   PubMed Web of Science ®Google Scholar
• ChenJLuYZhengYIncidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trialsDrug Des Devel Ther2015947514760
   Web of Science ®Google Scholar
• BrufskyAMHurvitzSPerezERIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol201129324286429321990397
   PubMed Web of Science ®Google Scholar
• GianniLRomieuGHLichinitserMAVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerJ Clin Oncol201331141719172523569311
   PubMed Web of Science ®Google Scholar
• MartinMRocheHPinterTTRIO 010 investigatorsMotesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyLancet Oncol201112436937621429799
   PubMed Web of Science ®Google Scholar
• MillerKDChapLIHolmesFARandomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancerJ Clin Oncol200523479279915681523
   PubMed Web of Science ®Google Scholar
• AnMMZouZShenHIncidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysisEur J Clin Pharmacol201066881382120401474
   PubMed Web of Science ®Google Scholar
• ZhuXWuSDahutWLParikhCRRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysisAm J Kidney Dis200749218619317261421
   PubMed Web of Science ®Google Scholar
• RanpuraVPulipatiBChuDZhuXWuSIncreased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysisAm J Hypertens201023546046820186127
   PubMed Web of Science ®Google Scholar
• LiQYanHZhaoPYangYCaoBEfficacy and safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer: a meta-analysis of randomized controlled trialsSci Rep201551574626503902
   PubMed Web of Science ®Google Scholar
• DiérasVCamponeMYardleyDARandomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerAnn Oncol20152691904191026202594
   PubMed Web of Science ®Google Scholar
• DiérasVWildiersHJassemJTrebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: a phase 2 randomized studyBreast201524318219025747197
   PubMed Web of Science ®Google Scholar
• MartínMLoiblSvon MinckwitzGPhase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) studyJ Clin Oncol20153391045105225691671
   PubMed Web of Science ®Google Scholar
• MilesDCameronDBondarenkoIBevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationEur J Cancer20177014615527817944
   PubMed Web of Science ®Google Scholar
• von MinckwitzGPuglisiFCortesJBevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trialLancet Oncol201415111269127825273342
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGøtzschePCCochrane Bias Methods Group; Cochrane Statistical Methods GroupThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• SchneiderBPWangMRadovichMECOG 2100Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100J Clin Oncol200826284672467818824714
   PubMed Web of Science ®Google Scholar
• GampenriederSPRomederFMußCHypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysisAnticancer Res201434122723324403467
   PubMed Web of Science ®Google Scholar
• HurwitzHIDouglasPSMiddletonJPAnalysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studiesOncologist201318327328023485622
   PubMed Web of Science ®Google Scholar
• Launay-VacherVJanusNBeuzebocPTolérance rénovasculaire du bévacizumab dans le cancer du sein. Valeur pronostique de l’hypertension et de la protéinurie. [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]Bull Cancer201510211906914 French [with English abstract]26603517
   PubMed Web of Science ®Google Scholar
• SmithIPiergaJYBiganzoliLFinal overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trialBreast Cancer Res Treat2011130113314321830015
   PubMed Web of Science ®Google Scholar
• SyrigosKNKarapanagiotouEBouraPManegoldCHarringtonKBevacizumab-induced hypertension: pathogenesis and managementBioDrugs201125315916921627340
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJEastern Cooperative Oncology Group Study E3200Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med2003349542743412890841
   PubMed Web of Science ®Google Scholar
• HamiltonEPBlackwellKLSafety of bevacizumab in patients with metastatic breast cancerOncology2011805–631432521778772
   PubMed Web of Science ®Google Scholar
• ShenBQLeeDYZioncheckTFVascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathwayJ Biol Chem199927446330573306310551875
   PubMed Web of Science ®Google Scholar
• SteeghsNGelderblomHRoodtJOHypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitorClin Cancer Res200814113470347618519779
   PubMed Web of Science ®Google Scholar
• IzzedineHRixeOBillemontBBaumelouADerayGAngiogenesis inhibitor therapies: focus on kidney toxicity and hypertensionAm J Kidney Dis200750220321817660022
   PubMed Web of Science ®Google Scholar
• SugimotoHHamanoYCharytanDNeutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuriaJ Biol Chem200327815126051260812538598
   PubMed Web of Science ®Google Scholar
• IzzedineHEderhySGoldwasserFManagement of hypertension in angiogenesis inhibitor-treated patientsAnn Oncol200920580781519150949
   PubMed Web of Science ®Google Scholar
• BottiglieriSMulunehBSutphinSIacovelliLAdamsVBlood pressure control in patients receiving bevacizumab in an outpatient cancer centerJ Oncol Pharm Pract201117433333820817652
   PubMedGoogle Scholar
• MirOCoriatRRopertSTreatment of bevacizumab-induced hypertension by amlodipineInvest New Drugs201230270270720878444
   PubMed Web of Science ®Google Scholar
• MilesDWde HaasSLDirixLYBiomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerBr J Cancer201310851052106023422754
   PubMed Web of Science ®Google Scholar
• Etienne-GrimaldiMCFormentoPDegeorgesAProspective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patientsBr J Clin Pharmacol201171692192821204912
   PubMed Web of Science ®Google Scholar
• MaitlandMLBakrisGLBlackHRCardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering CommitteeInitial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsJ Natl Cancer Inst2010102959660420351338
   PubMedGoogle Scholar
• De StefanoACarlomagnoCPepeSBiancoRDe PlacidoSBevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patientsCancer Chemother Pharmacol20116851207121321409384
   PubMed Web of Science ®Google Scholar
• MirOCoriatRCabanesLAn observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOncologist20111691325133221807768
   PubMed Web of Science ®Google Scholar
• ÖsterlundPSoveriLMIsoniemiHPoussaTAlankoTBonoPHypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapyBr J Cancer2011104459960421304526
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol201028132137214320368558
   PubMed Web of Science ®Google Scholar
• ScartozziMGaliziaEChiorriniSArterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumabAnn Oncol200920222723018842611
   PubMed Web of Science ®Google Scholar